The city of Springfield is following in the steps of other large employers in filing suit against manufacturers of diabetes ...
More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached ...
They also stalled their review of French drugmaker Sanofi's Tzield for late-stage type 1 diabetes by more than a month over ...
Ocular Therapeutix’s lead asset is Axpaxli, being developed for wet age-related macular degeneration. A Phase III study is ...
Sanofi has secured regulatory approval in China for two innovative medicines, Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome. The approvals ...
The FDA has delayed reviews of drugs under its fast-track program due to safety and efficacy concerns, including trial data issues and adverse events. This includes Disc Medicine's rare blood disorder ...
Stocktwits on MSN
Disc Medicine, Sanofi, Eli Lilly shares slip on reports of FDA increasing review time for drugs granted priority review vouchers
FDA is slated to decide on Disc Medicine's Bitopertin by February. ・Approval for Lilly’s obesity pill is expected by April 10 ...
Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite ...
Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Select Fund” fourth-quarter 2025 investor letter.
Ocular Therapeutix (OCUL) added ~21% in the premarket on Thursday after the French publication La Lettre reported that Sanofi (SNY) is readying an improved takeover offer to acquire the U.S. eye ...
FDA delayed fast-track reviews for multiple drugs after safety and efficacy concerns, including adverse events and a reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback